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Abstract
Background: Amplified centrosomes are widely recognized as a hallmark of cancer. Although supernumerary
centrosomes would be expected to compromise cell viability by yielding multipolar spindles that results in death-
inducing aneuploidy, cancer cells suppress multipolarity by clustering their extra centrosomes. Thus, cancer cells, with
the aid of clustering mechanisms, maintain pseudobipolar spindle phenotypes that are associated with low-grade
aneuploidy, an edge to their survival. KIFC1, a nonessential minus end-directed motor of the kinesin-14 family, is a
centrosome clustering molecule, essential for viability of extra centrosome-bearing cancer cells. Given that ovarian
cancers robustly display amplified centrosomes, we examined the overexpression of KIFC1 in human ovarian tumors.
Results: We found that in clinical epithelial ovarian cancer (EOC) samples, an expression level of KIFC1 was significantly
higher when compared to normal tissues. KIFC1 expression also increased with tumor grade. Our In silico analyses
showed that higher KIFC1 expression was associated with poor overall survival (OS) in serous ovarian adenocarcinoma
(SOC) patients suggesting that an aggressive disease course in ovarian adenocarcinoma patients can be attributed to
high KIFC1 levels. Also, gene expression levels of KIFC1 in high-grade serous ovarian carcinoma (HGSOC) highly
correlated with expression of genes driving centrosome amplification (CA), as examined in publically-available
databases. The pathway analysis results indicated that the genes overexpressed in KIFC1 high group were associated
with processes like regulation of the cell cycle and cell proliferation. In addition, when we performed gene set
enrichment analysis (GSEA) for identifying the gene ontologies associated to KIFC1 high group, we found that the first
100 genes enriched in KIFC1 high group were from centrosome components, mitotic cell cycle, and microtubule-
based processes. Results from in vitro experiments on well-established in vitro models of HGSOC (OVSAHO,
KURAMOCHI), OVCAR3 and SKOV3) revealed that they display robust centrosome amplification and expression levels of
KIFC1 was directly associated (inversely correlated) to the status of multipolar mitosis. This association of KIFC1 and
centrosome amplification with HGSOC might be able to explain the increased aggressiveness in this disease.
Conclusion: These findings compellingly underscore that KIFC1 can be a biomarker that predicts an aggressive disease
course in ovarian adenocarcinomas.
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Background
Ovarian cancer is the sixth most common cancer affecting
women worldwide and is the fifth leading cause of deaths
related to gynecological malignancies with less than 40 %
overall cure rate [1]. The overall mortality of ovarian
cancer has remained largely unchanged over the past de-
cades even though there is a great advancement in surgical
and therapeutic approaches [2]. The standard treatment
for ovarian cancer patients is debulking surgery followed
by a platinum- based chemotherapy (cisplatin and carbo-
platin) [3, 4]. One of the primary causes of the high mor-
tality and poor survival in ovarian cancer is the diagnosis
at late stages [5]. Despite years of extensive research, there
is still a dearth of reliable biomarkers for early detection,
prognosis, and predicting disease aggressiveness. Since
ovarian cancer is a heterogeneous disease with different
histopathological features and clinical behavior, a better
understanding of molecular subtypes and search for
clinically-facile prognostic factors that can aid in histo-
logical subtyping is imperative. Greater than 90 % of malig-
nant ovarian tumors are epithelial ovarian carcinomas
(EOC) comprising of various subtypes namely serous,
endometrioid, clear cell, transitional cell, squamous cell and
mucinous carcinomas [6, 7]. About 70–80 % of all cases are
serous ovarian cancer (SOC) among which high-grade ser-
ous ovarian cancer (HGSOC) is the most prevalent [8]. In-
triguingly, HGSOC shares similar genomic features with
triple negative breast cancer (TNBC) as per reports from
Cancer Genome Atlas (TCGA) Network analysis; in par-
ticular, the deregulated pathways characterizing HGSOC
are very similar to those in TNBC [9]. Several independent
studies have indicated that HGSOC is associated with very
high genomic instability and chromosomal aberrations in-
cluding intrachromosomal breaks and aneuploidy, which
incidentally, also typify and drive intratumoral heterogen-
eity in TNBC [10, 11].
Specifically, the most common mutations present in
both kinds of tumors (HGSOC and TNBC) are of p53
and BRCA1/2. It is well established that BRCA1 and
BRCA2 tumor suppressor genes directly preserve gen-
omic stability by regulating DNA repair, p53-mediated
cell cycle checkpoint control as well as centrosome du-
plication cycle [12–14]. These findings establish the
causative link between BRCA1 and BRCA2 mutations
and extensive chromosomal instability found in HGSOC
patients. Furthermore, HGSOC tumors frequently overex-
press cyclin E and Aurora-A, resulting in aberrant activa-
tion of the centrosome duplication cycle that induces
centrosome amplification (CA), and eventually genetic in-
stability fueling ovarian cancer progression [15–17]. CA
results in numerous and voluminous centrosomes [18].
Subjectively, the presence of supernumerary centrosomes
sets the stage for the formation of multipolar spindles that
may succumb to a mitotic catastrophe. However, cancer
cells avoid this calamitous fate by clustering their extra
centrosomes at the two spindle poles, which allows them
to evade cell death but ultimately engenders low-grade an-
euploidy and genetic instability [19–21].
KIFC1, a nonessential kinesin motor protein, also
known as HSET, plays a critical role in clustering of extra
centrosomes in cancer cells. Recently several studies have
shown that knockdown of KIFC1 in cancer cell lines con-
taining supernumerary centrosomes causes the excess
centrosomes to be scattered by pole-separating forces that
induce spindle multipolarity and cell death. However,
KIFC1 is not required for bipolar spindle assembly in
healthy somatic cells [22, 23]. We recently demonstrated
that EOC clinical samples harbor extra centrosomes and
display high levels of centrosome clustering in interphase
as well as mitosis. In addition, the study highlighted that
the gene expression levels of KIFC1 are higher in EOC
when compared to normal ovarian tissues in silico and is
associated with worse prognosis and survival [24]. To fur-
ther understand and validate results of our previous study,
we herein evaluated KIFC1 expression in clinical samples
of ovarian cancer by utilizing immunohistochemical stain-
ing. Our results indicated higher KIFC1 expression in
EOC tumor samples when compared to normal tissues.
Furthermore, KIFC1 expression levels in EOC increased
with an increase in tumor grade. To understand better the
association of KIFC1 with CA, we examined correlations
between expression levels of KIFC1 and genes driving CA.
Intriguingly, higher gene expression levels of KIFC1 was
significantly correlated to expression of CA-driving genes.
When GSEA was performed for the genes enriched in
KIFC1-high group, they were also found to be related to
centrosome components and microtubule-based pro-
cesses. We further validated the correlation by doing
quantitative analysis of CA and extent of clustering in cell
lines derived from SOC patients. Our results indicated
that KIFC1 was highly expressed in these in vitro models
of SOC and was also associated to levels of centrosome
clustering (mitotic), enabling cells to bypass mitotic
catastrophe.
Taken together our findings underscore that KIFC1 is
a potential prognostic biomarker in ovarian adenocarcin-
omas wherein expression levels of KIFC1 may predict
the course of disease aggressiveness. Work is underway
in our laboratory to pin point molecular mechanism to
explain the association of KIFC1 and CA with ovarian
cancer aggressiveness and poor patient outcomes.
Results
KIFC1 is overexpressed in Epithelial Ovarian
adenocarcinoma (EOC) clinical samples
We first examined whether KIFC1 is upregulated in
human ovarian cancers by analyzing KIFC1 overex-
pression in EOC clinical samples. To this end, we
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immunostained paraffin-embedded formalin-fixed tissue
microarrays of EOC (n = 120) and normal ovarian epithe-
lial tissue (n = 13) for KIFC1. The staining intensity was
scored as 0 = none, 1 = low, 2 = moderate, or 3 = high,
and percentage of positive cells (i.e., with 1+ staining
intensity) from randomly selected fields (~500 cells)
was determined [18]. The product of the staining in-
tensity and the percent of positive cells constituted the
Weighted Index (WI). Descriptive statistics regarding
patient and clinicopathological characteristics is given
in Tables 1 and 2. In consonance with our previously
published study [24], our immunohistochemical ana-
lysis showed overexpression of KIFC1 in EOC tissues
with negligible expression in normal ovarian epithelial
tissue (Fig. 1A). We found that the number of positively-
stained nuclei per field in high-grade ovarian cancers
(Fig. 1A) was significantly higher compared to low-grade
ones. We then compared the nuclear KIFC1 WI values for
normal and tumor samples and also across grades for
tumor samples. Interestingly, we observed that nuclear
KIFC1 WI was significantly higher in EOC tissues when
compared to normal tissues (p < 0.01). Also, the nuclear
KIFC1 WI increased with increasing tumor grade
(Figure 1Bii) (p < 0.05). Among subtypes, we noticed that
the number of positively-stained nuclei per field in high-
grade serous ovarian cancers (Additional file 1: Figure S1A)
was significantly higher compared to low-grade serous
ovarian cancers (p < 0.05). Collectively, these observations
indicate robust KIFC1 overexpression in human ovarian
adenocarcinoma and strong association of KIFC1 expres-
sion levels with clinical progression of the disease. These
data suggest that KIFC1 might play an active role in driving
the progression of tumors into more malignant and aggres-
sive forms.
Enhanced KIFC1 gene expression is associated with poor
survival in HGSOC patients
Having established a significant correlation between KIFC1
expression and tumor differentiation, we next wanted to
determine if there is any association between KIFC1 gene
expression and clinical outcomes (overall survival (OS)) for
ovarian cancer patients. To this end, we examined single
channel microarray data from GEO (GSE9899) [25] to
compare the expression levels of KIFC1 among different
subtypes. Interestingly, we found that the gene expression
levels of KIFC1 were significantly higher in serous ovarian
adenocarcinoma (n = 154) when compared to all other sub-
types (Borderline serous adenocarcinoma, n = 18 and Peri-
toneal serous adenocarcinoma, n = 22) (Fig. 2A). Further,
we examined grade-wise trends in KIFC1 expression in ser-
ous ovarian adenocarcinoma. We observed a significant in-
crease in KIFC1 expression levels with increasing grade
(Fig. 2B). OS was calculated as the time interval (in
months) from the date of histological diagnosis to date of
death from any cause. We then carried out a survival
analysis wherein patients were stratified into high- and low-
KIFC1 expressing subgroups using the optimal KIFC1
expression cut-point (based on the log-rank test). Irrespect-
ive of the histological subtypes (n = 284), those with higher
KIFC1 expression had shorter OS (p < 0.067) than patients
with lower KIFC1 (Additional file 1: Figure S2A). To
investigate in-depth, we performed a similar survival
analysis by stratifying serous ovarian adenocarcinoma
patients (n = 201) on the basis of site (primary, n = 154
and metastatic, n = 47) of sample collection. Univariate
regression revealed high KIFC1 gene expression corre-
lated significantly (HR = 2.14, p = 0.024) with poor OS
in primary tumors only (Fig. 2C) but not in metastatic
ones (data not shown). This association stayed signifi-
cant (HR = 2.6, p = 0.006) during multivariate analysis
when potentially confounding factors like grade and
tumor stage were added (Additional file 1: Figure S2B).
In sum, enhanced gene expression level of KIFC1 in
primary tumors is strongly associated with poor clin-
ical outcomes.
Table 1 Descriptive statistics for patient and clinicopathologic
characteristics in the analysis of KIFC1 levels in tumors and
matched normal tissue SD = standard deviation
Variable Level Number Percentage
Age 20–40 23 19.2
41–60 81 67.5
61< 16 13.3
Grade 1 32 26.7
2 36 30
3 46 38.3
Unknown 6 5
Stage I 69 57.5
II 31 25.8
III 12 10
IV 3 2.5
Unknown 5 4.2
Primary Tumor (T) T1 72 60
T2 31 25.8
T3 12 10
Unknown 5 4.2
Regional Lymph Nodes (N) N0 103 85.8
N1 12 10
Unknown 5 4.2
Distant metastasis Yes 3 2.5
No 112 93.3
Unknown 5 4.2
Tissue type Malignant 115 95.8
Metastasis 5 4.2
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KIFC1 gene expression correlates with expression of
genes related to centrosomal amplification in serous
ovarian cancer
Next, we sought to examine the correlation of KIFC1
and genes driving CA. We analyzed expression levels
of genes including CCNA2, CDK1, NEK2, AURKA,
MYCN, CCNE2, STIL, LMO4, PLK4, MDM2, CEP63,
E2F1, E2F2, E2F3, CEP152, PIM1, PIN1 andCCND1,
whose deregulation is known to drive CA [18, 26–28].
Specifically, we tested the associations between Robust
Multi-array Average-normalized expression levels of these
genes in primary SOC from 154 patients using Gene
Expression Omnibus (GEO) series GSE9899. Higher ex-
pression of KIFC1 was significantly correlated with high
expression of CCNA2, CDK1, NEK2, AURKA, E2F2,
MYCN, STIL, CCNE2, E2F3, LMO4, PLK4, PIN1 and
E2F3 (Table 4). These results suggest that KIFC1 upregu-
lation and enhanced centrosome clustering in the serous
ovarian adenocarcinomas may enable tumor cells to man-
age their increased centrosomal load, avert mitotic catas-
trophe and promote survival.
Next, we identified the biological processes which are
deregulated in the KIFC1 high risk group. To this end, we
probed the publicly-available microarray dataset (GSE9899)
and stratified the 154 serous ovarian adenocarcinoma pa-
tients from the dataset into KIFC1-high and KIFC1-low
groups. We then identified the gene ontologies of signifi-
cantly overexpressed genes associated with the KIFC1-high
group utilizing the PANTHER classification system. When
pathway analysis was performed we found that majority of
the genes overexpressed were associated to cellular pro-
cesses like cell communication, cell cycling, cytokinesis and
cell proliferation (Fig. 3Ai, ii). We then validated these results
by performing the Gene set enrichment analysis (26). We
found that KIFC1 high group was significantly (Fdr <0.25
and ES p < 0.05) enriched in centrosome and cell cycle
gene sets (Fig. 3Bi,ii and Additional file 1: Figure S3A)
Table 2 Description of the subtypes of epithelial ovarian cancer
for clinical samples included in the anlaysis of KIFC1 levels
Variable Level Number Percentage
Pathological
diagnosis
Adenocarcinoma 2 1.7
Serous Adenocarcinoma 6 5
Serous Papillary
Adenocarcinoma
3 2.5
Endometrioid
Adenocarcinoma
10 8.3
Metastatic Adenocarcinoma 4 3.3
Metastatic Mucinous
Adenocarcinoma
1 0.8
Mucinous Adenocarcinoma 11 9.2
Clear Cell Carcinoma 4 3.3
Serous Papillary Carcinoma 32 26.7
Serous Papillary
Cystadenocarcinoma
47 39.2
Fig. 1 High grade epithelial ovarian carcinomas exhibit higher expression of KIFC1 than low-grade adenocarcinomas and uninvolved, adjacent
normal tissues. A Low magnification (4x) and their corresponding higher magnification (20x) images depicting KIFC1 expression in normal, low-grade
and high-grade EOC tissues. The tissues were stained for KIFC1 (brown) and nuclei (blue). Scale bar (red) 20 μm. Bi Box-whisker plot
depicting the weighted index (WI) of KIFC1 expression in normal and tumor tissue. Bii Box-whisker plot representing the WI for KIFC1
expression in low and high-grade EOC samples
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(see Additional file 1: Tables S1, S2 and S3 for these
and all other enriched gene ontologies). The results
from GSEA showed that the top 100 gene sets
enriched in KIFC1 high group were among the ones
which plays key roles in, driving CA (NEK2,
PLK1,CCNA2), clustering centrosomes (PRC1), micro-
tubule spindle (KIF11, NUSAP1, NUMA1) etc.
Altogether our data shows that the KIFC1-high group
had a preponderance of genes representing all four
important mitotic kinases –namely Polo-like kinases
(PLK1), Aurora kinases (AURKA, AURK B), cyclin
dependent kinases (CDK1) and NIMA related kinases
(NEK1, NEK2). The coordination of progression
through mitosis is mainly orchestrated by protein
phosphorylation ensured by these kinases. Thus, it is
reasonable to speculate that overexpression of these
kinases results in deregulation of the cell cycle result-
ing in abnormal mitosis that generates cells with
aberrant centrosomes and abnormal chromosomal
content.
HGSOC cell lines show higher incidence and severity of
centrosome amplification
Having confirmed the association between upregulation of
KIFC1 gene and CA genes in HGSOC, we wanted to in-
vestigate the CA profile in well-established in vitro cell
lines that mimic HGSOC. To this end, we first screened
four well-established cancer cell lines (namely, KURA-
MOCHI, OVCAR3, OVSAHO and SKOV3 by immuno-
staining centrosomes (γ-tubulin, green) and microtubules
(α-tubulin, red) and counterstaining nuclei with DAPI
(blue) Fig. 4a. Employing confocal microscopy we imaged
10 areas of interest (at least 500 cells were counted per cell
type). Cells with abnormal number (more than two) of
gamma tubulin spots were considered as cells with ampli-
fied centrosomes. We found that KURAMOCHI exhibited
the highest percentage of cells with amplified centrosomes
(~38 %) followed by OVSAHO (~24 %), OVCAR3
(~15 %) and SKOV3 (~9 %) (Fig. 4b). In a recent molecu-
lar profiling study by Domcke et al., KURAMOCHI and
OVSAHO were selected as the representative cell lines for
HGSOC [29]. Thus, our findings here parallel previous
studies that recognize CA as a biomarker of aggressive
tumors. Furthermore, we validated our results by evaluat-
ing the expression levels of centrosome-related proteins
by performing immunoblotting assays. We found that the
cell lines with high CA (KURAMOCHI and OVSAHO)
expressed higher levels of centrosome structural proteins
(densitometry values for centrin-2 relative to loading
control β actin (KURAMOCHI - 0.291445, OVSAHO -
0.432561) and proteins whose dysregulation is known to
drive CA (for Cyclin-E and Aurora A, KURAMOCHI-
0.194213 and 0.256828, OVSAHO- 0.428814, 1.664283
respectively) (Fig. 4c). Our next step was to investigate if
aberrations in centrosome numbers among the different
cell lines had any bearing on the mitotic spindle geometry.
Interestingly, we found that the percentage of multipolar
mitotic cells in three cell lines (OVSAHO, SKOV3 and
OVCAR3) was lower (by 2 fold) in comparison with the
proportion of cells with supernumerary centrosomes
(Fig. 4b). This difference in the proportion of cells with CA
and multipolar spindles clearly supports the hypothesis that
ovarian cancer cells cluster supernumerary centrosomes to
form pseudobipolar poles. But as the results here indicate
that KURAMOCHI showed significantly more multipolar
mitoses when compared to the other ovarian cancer cell
lines we tested, we evaluated if there existed variability in
the level of clustering molecules that help cancer cells to
deal with supernumerary centrosomes by corralling them
to form pseudobipolar spindles [24]. To this end, we per-
formed immunoblotting to evaluate expression level of
centrosome clustering protein KIFC1 in cell lysates
Table 3 Descriptive statistics and clinicopathologic
characteristics for patients included in in silico analysis of KIFC1
expression and overall survival
Variable Level Number Percentage
Age (Range) 20–29 1 0.5
30–39 4 1.9
40–49 23 11.1
50–59 84 40.4
60–69 54 26
70–79 40 19.2
80–89 1 0.5
Unknown 1 0.5
Cancer site Primary 154 74
Metastasis 50 24
Unknown 4 1.9
FIGO Stage I 9 4.3
II 9 4.3
III 126 60.6
IV 10 4.8
Unknown 54 26
Grade 1 6 2.9
2 80 38.5
3 120 57.7
Unknown 2 1
Survival Status Alive 109 52.4
Dead 98 47.1
Unknown 1 0.5
Recurrence Recurrence 154 74
No Recurrence 53 25.5
Unknown 1 0.5
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obtained from the ovarian adenocarcinoma cells (KURA-
MOCHI, OVCAR3, OVSAHO and SKOV3). We found
that all the three cell lines with pronounced centrosomal
clustering expressed higher levels of KIFC1 (SKOV3-
0.342396, OVCAR3- 0.204796 and OVSAHO- 0.452534)
whereas negligible KIFCI expression was noted in KURA-
MOCHI (0.145452). It is noteworthy to mention that a re-
cent report shows that KURAMOCHI is the only cell line
that did not induce tumorigenesis in vivo [11]. This finding
resonates with our notion that centrosome clustering is es-
sential for the viability of cancer cells with extra centro-
somes and therefore determines their tumorigenicity.
The in vitro findings were validated in silico by probing
publically-available microarray dataset using Gene set. We
interrogated publically-available microarray dataset of
ovarian cancer cell lines (GSM133614, GSM133609,
GSM887467 and GSM887488). We calculated a cumulative
gene expression-based centrosome amplification index
(CAI) by adding log-transformed, normalized gene expres-
sion for both structural centrosomal proteins (CETN2
(centrin-2), TUBG1 (γ-tubulin), PCNT2 (pericentrin)), and
genes implicated in centrosome amplification (PLK4 (polo-
like kinase 4) and CCNE1 (cyclin E) genes) (Additional file
1: Fig. S4 Ai). The analysis showed that CAI genes are
expressed in all cell lines but is highest in OVSAHO. In
Fig. 2 KIFC1 is highly expressed in High grade serous ovarian adenocarcinoma and is associated with poor overall survival. A Box-whisker graphs
depicting the expression levels of KIFC1 among different subtypes of ovarian cancer. B Box- whisker graphs depicting the expression levels of
KIFC1 in serous ovarian adenocarcinoma in different tumor grades. Ci Kaplan-Meier plots showing overall survival of HGSOC patients based on
low or high expression of KIFC1 gene. Cii Summary of the number of censored and uncensored values for the Kaplan-Meier survival analysis
Table 4 Correlation between expression levels of KIFC1 and
genes whose dysregulation drives centrosome amplification
Gene Pearson correlation P-Value
CCNA2 0.62527 <.0001
NEK2 0.60066 <.0001
E2F1 0.54218 <.0001
CDK1 0.52124 <.0001
E2F2 0.51764 <.0001
AURKA 0.46987 <.0001
STIL 0.397 <.0001
CCNE2 0.36387 <.0001
LMO4 0.36306 <.0001
PLK4 0.34292 <.0001
MYCN 0.31914 <.0001
E2F3 0.31548 <.0001
MDM2 0.24766 0.002
PIN1 0.23016 0.0041
CEP152 0.18128 0.0245
PIM1 0.17826 0.027
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addition, we evaluated gene expression levels of KIFC1 and
found that the gene expression levels of KIFC1 were higher
in cancer cell lines in comparison to normal ovarian surface
epithelial cells (Additional file 1: Figure S4 Aii). Taken to-
gether, our results indicated that CA and KIFC1 levels are
associated with HGSOC cell lines.
Discussion
Ovarian cancer in the advanced stage remains the dead-
liest gynecologic malignancy. One of the major causes of
the low five-year survival is the diagnosis at later stages
after it has already metastasized beyond the pelvis [30].
While extensive literature contains information on the
different kinds of biomarkers for ovarian cancer, risk
predictive or prognostic markers that are utilized in clin-
ical settings are few and far between. Generally, most re-
searchers focus on single prognostic markers which may
be insufficient for complete prognostic information, and
also most of them have very low clinical utility. A com-
bination of multiple factors needs to be considered simul-
taneously to more accurately predict a patient’s prognosis.
Presence of heterogeneity in ovarian cancer is another key
factor to be considered in prognosis as many ovarian can-
cer studies have failed to take into account differences in
the histological subtype which clearly pose prognostic and
therapeutic challenges [30, 31]. Essentially, these unique
attributes and challenges can be addressed by personaliz-
ing treatments based upon the unique biomarker profiles
Fig. 3 Gene set enrichment analyses for biological processes associated to KIFC1 high group. Ai Biological processes enriched in KIFC1 high
group. Aii Cell cycle processes enriched in KIFC1-high group. Bi Enrichment plots of centrosome-related genes. Bii Enrichment plot of genes
associated with cell cycle progression, with red indicating correlation with the KIFC1-high group and blue the KIFC1-low group
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of individual patients. Thus, a comprehensive understand-
ing of risk predictive or prognostic factors with regard to
histological subtype is imperative to devise relevant treat-
ment strategies specific for the particular group of
patients or tumor subtypes.
Chromosomal instability (CIN) is the main cause of com-
plex genomic alterations in tumorigenesis. Since CA engen-
ders CIN, the role of CA driven karyotypic diversity is well
studied in several malignancies including pancreatic ductal
adenocarcinoma, TNBC and colon cancer [18, 20]. Several
studies have highlighted the presence of supernumerary
centrosomes in ovarian cancer suggesting that CA is a hall-
mark of ovarian cancer [32–34]. Recently, we also demon-
strated the presence of amplified centrosomes in EOC [24].
Supernumerary centrosomes in cancer cells tend to cluster
to manage the centrosomal load and thus escape from the
perils of mitotic catastrophe. KIFC1 is well studied for its
role in clustering supernumerary centrosomes [22, 23]. In
our previous study, we emphasized the role of KIFC1 in
tumor progression of EOC at the gene expression level
[24]. In the present study we have validated those findings
by immunostaining ovarian cancer tissue samples for
KIFC1. Our findings show that KIFC1 expression increases
with the grade in EOC. Among the various subtypes that
comprise EOC, we found that KIFC1 expression was
highest among high-grade SOC samples. This helped us to
focus our study on HGSOC, which is a more prevalent and
aggressive form of ovarian cancer. This strong relationship
of KIFC1 with HGSOC suggests that KIFC1 may be dir-
ectly involved in tumor development and in driving ag-
gressiveness by allowing the cancer/poorly differentiated
cells to escape mitotic catastrophe and thrive. Moreover,
data from our GSEA analysis showed that BIRC5 gene,
which codes for the protein Survivin, that performs dual
roles in promoting cell proliferation and preventing apop-
tosis [35, 36], was among the first 20 enriched genes in
KIFC1-high group. Thus, KIFC1 overexpression not only
protects cancer cells from undergoing mitotic catastrope
but also endows them with low-grade aneuploidy, as a
form of genomic instability, and high levels of survival sig-
naling that together facilitate tumor evolution and disease
progression. This finding was bolstered by results obtained
from in silico analysis wherein we found that primary tu-
mors with higher gene expression of KIFC1 were associ-
ated with poor survival; by contrast, while samples
collected from the metastatic sites showed similar expres-
sion levels of KIFC1 as in primary sites, high KIFC1
expression in metastatic sites was not significantly corre-
lated to poor survival. This differential effect of high
KIFC1 expression strongly suggests that elevated KIFC1
Fig. 4 HGSOC cell lines show higher incidence and severity of Centrosome amplification. a Confocal microscopic images showing the presence
of centrosome amplification and clustering in ovarian cancer cell lines. Centrosomes and microtubules were visualized by immunostaining for γ-tubulin
(green) and α-tubulin, respectively, and DNA was stained using DAPI (blue). Scale bar (white) 5 μm. b Bar graphical representation of percent cells showing
centrosome amplification and multipolar mitosis in human ovarian cancer cell lines. 500 cells were counted in each case. c Immunoblots showing the
levels of KIFC1 and centrosomal markers in ovarian cancer cells lines (KURAMOCHI, OVCAR3, OVSAHO, and SKOV3)
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in primary sites perhaps helps tumor cells present in the
primary sites to acquire karyotypic diversity (through
CIN), which is more likely to lead to successful metastasis
and poor survival. It is possible that once metastasis com-
mences, high KIFC1 levels in the metastatic clones pro-
vides little further survival advantage for the cancer cells;
alternatively, once metastasis occurs, the survival differ-
ence between KIFC1-high and KIFC1-low patients is no
longer so marked. Further studies are required to gain
more insights into these intriguing issues.
Given the direct association of CA with KIFC1 in the
present study, we examined the association of KIFC1
with CA-associated genes. Our in silico analysis indi-
cated that in primary SOC samples KIFC1 expression
was positively correlated to the expression of genes
which drive CA. CCNA2, NEK2, and AURKA were
among the top 10 genes which were highly correlated to
KIFC1 expression. Role of NEK2, CCNA2, and AURKA
as potential targets in ovarian cancer has been recently
highlighted by a detailed systematic bioinformatic study
[37]. Besides, this enrichment analysis showed that the
KIFC1-high group was enriched in genes implicated in
cell cycle regulatory processes, especially genes partici-
pating in G2-M transition and the spindle assembly
checkpoint (MAD2, BUB1). Several studies in past have
reported MAD1 and MAD2 overexpression in different
malignancies, and association of this overexpression with
aneuploidy and poor overall survival [38–40]. Thus, our
findings from the GSEA and Pathway analysis suggests that
KIFC1 overexpression drives overexpression of genes that
control mitotic checkpoints (Additional file 1: Table S2),
which by generating aneuploidy, accelerate tumor progres-
sion and evolution of more aggressive phenotypes.
In line with these in silico findings, we found that cell
line derived from HGSOC displayed robust CA, and the
proteins which are known to drive CA were also highly
expressed. Some recent studies on molecular profiling of
ovarian cell lines have demonstrated that OVSAHO rep-
resents most of the characteristics (KRAS, p53 and
BRCA1 and 2 mutations) of HGSOC [29] and is consid-
ered to be most aggressive cell line among all. From our
study, we found that OVSAHO cells expressed the high-
est levels of KIFC1 and in spite of presence of interphase
supernumerary centrosomes it showed significantly low
level of multipolar mitosis. These findings clearly indi-
cate that strong association of CA and clustering with
KIFC1 overexpression, which leads to CIN, could be the
underlying cause of aggressiveness in these cells. Testing
effects of centrosome declustering drugs on these cells
could prove to be advantageous.
Conclusions
Taken together our results indicate that HGSOC overex-
presses KIFC1, which is associated with poor overall
survival suggesting a causative link between KIFC1 and
tumor aggressiveness. These findings highlight KIFC1 as a
potential biomarker to predict disease aggressiveness KIFC1
may also serve as a cancer-selective therapeutic target for
high-grade serous ovarian adenocarcinoma patients.
Methods
Cell culture
The four ovarian cancer cell lines primarily utilized in this
study included OVCAR3, KURAMOCHI, SKOV3, and
OVSAHO. The SKOV3 and OVCAR3 cell lines were ob-
tained from ATCC and KURAMOCHI, and OVSAHO
were obtained from JCRB. All the cell lines were cultured
according to the instructions given by the company.
Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded tissue microarrays
(TMAs) for ovarian cancer were obtained from US,
Biomax, Inc. Company provided the ethical statement
to confirm that, all the participants provided their writ-
ten consents and patient privacy and anonymity was
maintained. TMAs were deparaffinized in a 60 °C oven
for 20 min and placed in 3 consecutive xylene washes.
Rehydration of the slides were carried out by putting
them through a series of washes involving different
concentrations of ethanol in water - 100 %, 95 %, 70 %,
and 50 % - for 3 min each. The antigen retrieval process
was done using a pressure cooker and 0.01 M citrate buf-
fer with a pH of 6.1. The slides were heated at a
temperature of 120 °C for 30 min. After cooling in ice for
20 min, the slides were first subjected to hydrogen perox-
ide blocking and then protein blocking (both obtained
from ThermoScientific) for 20 min and 10 min, respect-
ively. Tissues were incubated with anti-KIFC1 antibody
(Abcam) for 1 h, before incubating with MACH2 HRP-
conjugated secondary antibody (Biocare Medical) for
30 min. Enzymatic antibody detection using Betazoid
DAB Chromogen Kit (Biocare Medical) was followed by
nuclear staining with Myer’s hematoxylin (Dako). The
staining intensity was scored as 0 = none, 1 = low, 2 =
moderate, or 3 = high, and the percentage of KifC1-
positive cells from 10 randomly selected fields (~500 cells)
was determined. The product of the staining intensity and
the percent of positive cells constituted the WI. Statistical
analysis was performed using – Tukey’s post hoc test.
Cell staining and imaging
Cells were cultured on coverslips and, after the con-
fluency reached approximately 80 %, the cells were fixed
with ice-cold methanol for 7 min. The cells were
blocked with 5 % BSA/0.01 % Triton X for 45 min at
room temperature and then incubated at 37 °C with
antibodies directed against γ-tubulin and α-tubulin at a
dilution of 1:2000 for 30 min. The cells underwent quick
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washes 5 times with 1xPBS before being incubated with
Alexa Fluor 488 anti-mouse and Alexa Fluor 555 anti-
rabbit at a dilution of 1:2000 at 37 °C for 30 min. After
washing the cells 8 times with 1x PBS briefly, the cells
were then incubated with Hoechst 33342 (1:5000 dilu-
tion) at room temperature for 10 min. The cells were
mounted with Prolong-Gold antifade reagent after being
washed with 1x PBS 3 times and observed using Zeiss
LSM 700 Confocal microscope (Oberkochen, Germany)
and the images were processed with ZEN software
(Oberkochen, Germany).
Immunoblotting
Cell lysates were prepared from 80 % confluent cells by
scraping with 250ul of 1x lysis prepared from 10x cell
lysis buffer (Cell Signaling). The 1x lysis buffer contained
1 mM b-glycerophosphate, 20 mM Tris–HCl (pH 7.5),
1 mM Na2EDTA, 1 mM Na3VO4, 150 mM NaCl,
1 mM EGTA, 2.5 mM Na4P2O7, 1ug/ml leupeptin, and
1 % Triton. Cell lysates were fractionated using 10 %
SDS-PAGE gel. The samples were allowed to run at
70 V for 90 min. Protein transfer onto polyvinylidene
difluoride (PVDF) membrane was done for 2 h via the
wet transfer method at 70 V. The membrane was then
blocked in 5 % non-fat, dry milk in 1x TBST for 1 h at
room temperature and probed with the relevant anti-
bodies at a dilution of 1:1000 overnight at 4 °C. Primary
antibody incubation was followed by incubation with the
corresponding secondary antibody at a dilution of 1:
10,000 for 1 h at room temperature. SuperSignal West
Pico Chemiluminescent Substrate (ThermoScientific)
was directly applied to the membrane for the subsequent
analysis. Cyclin E and Centrin-2 antobodies were ob-
tained from Santa Cruz Biotech, γ-tubulin from Dako,
and KIFC1 and Aurora A antibodies from Abcam.
In silico analysis
One channel microarray data was downloaded from gene
expression omnibus (GEO) database for primary ovarian
cancer samples GSE 9899 [25]. Data was Mas5.0 normal-
ized and was further taken for processing. Logarithm to
the base 2-transformed KIFC1 expression levels from all
ovarian cancer samples (n = 284) regardless of histotypes
were extracted from GEO database. Further analysis were
carried only on the serous adenocarcinoma samples
(n = 200). Overall survival (OS) was calculated as the
time interval (in months) from the date of histological
diagnosis to date of death from any cause. KIFC1 was cat-
egorized into high and low groups based on the optimal
overall survival cut - points using the log-rank test.
Public microarray data analysis
Robust Multi-array Average normalized expression levels
of KIFC1 and genes which drive CA (CCNA2, CDK1,
NEK2, AURKA, MYCN, CCNE2, STIL, LMO4, PLK4,
MDM2, CEP63, E2F1, E2F2, E2F3, CEP152, PIM1, PIN1,
CCND1) from the primary serous ovarian carcinoma of
154 patients were obtained from GEO series GSE 9899
To obtain Pearson’s correlation coefficients between
genes whose dysregulation drives CA, SAS software
(IBM) was used for the analyses, with p < 0.05 indicating
statistical significance.
Gene set enrichment analysis of public microarray data
Publicly available pre-processed gene expression profiles of
primary ovarian tumors (n = 154 from Tothill dataset [25],
GSE9899; Patients were stratified into two groups by KIFC1
score. Patients with KIFC1 expressions below the optimal
KIFC1 survival threshold where placed in the low-risk
group whereas the above threshold patients where stratified
to the high-risk group. GSEA was performed as indicated
in studies by Tamayo, et al. (2005, PNAS 102, 15545–
15550) and Mootha, Lindgren, et al. (2003, Nat Genet 34,
267–273). False discovery rate q-values.25 were considered
statistically significant.
In silico analysis of KIFC1 gene expression and
centrosomal amplification index (CAI) genes in cell lines
One channel microarray data was downloaded from GEO
database for four cell lines with GSM ids GSM133614,
GSM133609, GSM887467 and GSM887488 namely,
Ovcar-5, SKOV3, OVSAHO, and OVCAR3 respectively.
Data was Mas5.0 normalized and was further taken for pro-
cessing. Logarithm to the base 2 transformed KIFC1 and
expression levels from ovarian cell lines were extracted
from the GEO database. PLK4, Aur-A, Aur B, Cyclin E,
Centrin, γ-tubulin and pericentrin genes expression values
were added to make centrosomal amplification index.
Statistical analysis
Statistical analyses were performed using two-tailed Stu-
dent’s t-tests, Anova and Tukey’s post hoc tests. The criter-
ion for statistical significance for all analyses was p < 0.05.
Standard errors were calculated using the general Excel for-
mula where we divided the standard deviation by the
square root of the number of samples. Kaplan-Meier ana-
lysis and Cox regression were performed using SPSS (IBM).
Optimal cut-points were identified with the stratification
which gave the largest log-rank χ2 value.
Additional file
Additional file 1: Supplementary Figures and Tables (DOCX 811 kb)
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